Metformin News and Research RSS Feed - Metformin News and Research

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.
Prolonged insulin therapy often unnecessary in children with Type 2 diabetes

Prolonged insulin therapy often unnecessary in children with Type 2 diabetes

Many children who require insulin treatment on diagnosis with Type 2 diabetes can be weaned off the medication, show findings from the run-in phase of the Treatment Options for Type 2 Diabetes in Adolescents and Youth study. [More]
Vitamin D3 and metformin show promising results in preventing colorectal cancer

Vitamin D3 and metformin show promising results in preventing colorectal cancer

The concept was simple: If two compounds each individually show promise in preventing colon cancer, surely it's worth trying the two together to see if even greater impact is possible. [More]
Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid. [More]
Study: Combination of metformin and onion extract lowers blood glucose, total cholesterol levels

Study: Combination of metformin and onion extract lowers blood glucose, total cholesterol levels

The extract of onion bulb, Allium cepa, strongly lowered high blood glucose (sugar) and total cholesterol levels in diabetic rats when given with the antidiabetic drug metformin, according to a new study. [More]
UT Southwestern scientists identify new biomarker that could optimize chemotherapy response

UT Southwestern scientists identify new biomarker that could optimize chemotherapy response

UT Southwestern Medical Center scientists have identified a new biomarker that could help identify patients who are more likely to respond to certain chemotherapies. [More]
Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. announced today top-line results from a Phase 2 study of ISIS-PTP1B Rx in patients with type 2 diabetes. In the Phase 2 study patients treated with ISIS-PTP1B Rx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c). [More]
Study clarifies association between metformin use and lung cancer risk

Study clarifies association between metformin use and lung cancer risk

Among nonsmokers who had diabetes, those who took the diabetes drug metformin had a decrease in lung cancer risk, according to a study in Cancer Prevention Research, a journal of the American Association for Cancer Research, by Lori Sakoda, PhD, MPH, research scientist at the Kaiser Permanente Division of Research in Oakland, California. [More]
Purdue University researchers find promising way to treat late-stage prostate cancer

Purdue University researchers find promising way to treat late-stage prostate cancer

Low doses of metformin, a widely used diabetes medication, and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue University study finds. [More]
Certain patients with type 2 diabetes, renal impairment discouraged from taking metformin

Certain patients with type 2 diabetes, renal impairment discouraged from taking metformin

Many patients with type 2 diabetes in the United States may be discouraged from taking metformin—a proven, oral diabetes medicine—because the U.S. Food and Drug Administration inappropriately labels the drug unsafe for some patients also suffering from kidney problems, researchers from Penn Medicine and Weill Cornel Medical College report this week in a research letter published in JAMA Internal Medicine. [More]
Diabetes drug can boost efficacy of TB medication without causing drug resistance

Diabetes drug can boost efficacy of TB medication without causing drug resistance

A more effective treatment for tuberculosis (TB) could soon be available as scientists have discovered that Metformin (MET), a drug for treating diabetes, can also be used to boost the efficacy of TB medication without inducing drug resistance. [More]
Alizé Pharma completes two Phase I clinical trials of AZP-531 in healthy volunteers, obese subjects

Alizé Pharma completes two Phase I clinical trials of AZP-531 in healthy volunteers, obese subjects

Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announces today the completion of two Phase I clinical trials with its unacylated ghrelin analog AZP-531 in 76 healthy volunteers and overweight or obese subjects. [More]
Behavioural, drug interventions aiming to prevent progression to diabetes equally effective for both sexes

Behavioural, drug interventions aiming to prevent progression to diabetes equally effective for both sexes

Behavioural and drug interventions aiming to prevent people with prediabetes progressing to full blown type 2 diabetes are equally effective for both sexes at preventing progression and reducing weight, according to a new systematic review and meta-analysis. [More]
Researchers use EHRs to uncover hidden drug benefits

Researchers use EHRs to uncover hidden drug benefits

With research and development costs for many drugs reaching well into the billions, pharmaceutical companies want more than ever to determine whether their drugs already at market have any hidden therapeutic benefits that could warrant putting additional indications on the label and increase production. [More]
No added benefit proven for empagliflozin in type 2 diabetes

No added benefit proven for empagliflozin in type 2 diabetes

Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. [More]
Diabetes treatment with low-cost generic drug can have positive implications for patient's quality of life

Diabetes treatment with low-cost generic drug can have positive implications for patient's quality of life

New research from CVS Health finds starting a new diabetes patient on metformin, a generic oral diabetes medicine that helps control blood sugar levels, reduced the need to add on additional treatments to control the condition over time. Although there are many classes of oral diabetes medications, there has historically been little evidence available on the comparative effectiveness of treatments to help patients and providers select an initial diabetes therapy. [More]
Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%. [More]
MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

MicroBiome TherapeuticsTM LLC, today reported positive topline results from a proof of concept study testing whether its investigational drug, NM 505, can improve the tolerability of metformin, the first-line therapy for Type 2 diabetes worldwide. [More]
Treating prediabetes patients could help prevent severe complications associated with diabetes

Treating prediabetes patients could help prevent severe complications associated with diabetes

Doctors at three leading research institutions and the American Diabetes Association report that treating patients with prediabetes as if they had diabetes could help prevent or delay the most severe complications associated with this chronic disease, which affects about thirty million people in the United States. [More]
AMPK gene can slow aging process when activated remotely in key organ systems

AMPK gene can slow aging process when activated remotely in key organ systems

UCLA biologists have identified a gene that can slow the aging process throughout the entire body when activated remotely in key organ systems. [More]
Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. [More]
Advertisement
Advertisement